Navigation Links
Chewable Tablet Might Offer New Help for Diabetes Patients
Date:1/8/2014

MANCHESTER, N.H., Jan. 8, 2014 /PRNewswire/ -- Among those with Type 2 diabetes, the body either resists the effects of insulin, or the pancreas doesn't produce enough insulin to maintain a normal glucose level. What if these patients implemented a healthier diet and regular exercise?

According to R. Paul Robertson, M.D., president, Medicine and Science, of the American Diabetes Association, diabetes can be made to go into remission, but it will always be there. But, he says, patients can make significant strides against the disease, often to the point of quitting medication. The good news is that for some people who have lost weight, kept blood sugar levels stable, eat right and work out, doctors may allow them to go off their medications. 

As researchers strive for improved treatment options, the best one can do right now is to eat right, exercise and watch for complications. Oh, and one more thing: watch for PAZ320. Currently being developed by Boston Therapeutics, Inc., a Manchester, NH-based pharmaceutical company, PAZ320 is a non-systemic, non-toxic chewable drug candidate that is designed to inhibit enzymes that release glucose from complex carbohydrates in foods during digestion. In a Phase IIa study last year, 45 percent of Type 2 diabetes patients taking metformin responded to PAZ320 with a 40 percent reduction of post-meal glucose in the blood. 

David Platt, Ph.D., Boston Therapeutics' CEO, explains that they set out to make one molecule that would block enzymes that participate in the digestion of sugar. The resulting polysaccharide—a new class of drugs called carbohydrate hydrolyzing enzyme inhibitors (CHEI)—is taken before meals, working in the gastrointestinal tract to "disable" the carbs. In other words, it blocks the action of carbohydrate-hydrolyzing enzymes that break carbohydrates down into glucose.

As they wait for new treatments, Type 2 diabetes patients might one day benefit from this chewable "disabler."

For more, visit www.bostonti.com, who paid for the writing and dissemination of this release.

Contact:  Laura Radocaj, Dian Griesel Int'l.  212.825.3210


'/>"/>
SOURCE Boston Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Launches Generic Version of Zyprexa® Tablets
2. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
3. Mylan Launches Generic Version of Plavix® Tablets
4. Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN)
5. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
6. Mylan Launches Generic Version of Viramune® Tablets
7. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
8. FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet
9. Jentadueto® (linagliptin/metformin hydrochloride) tablets recommended for approval in the treatment of adults with type 2 diabetes in Europe
10. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
11. Qualitest Receives FDA Approval for Levetiracetam Extended-Release Tablets, 500mg and 750mg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  True Health, a ... amplified its effort during National Breast Cancer Awareness ... cancer risks. ... Oncology calculated that more than 10 million American ... mutations in BRCA1 or BRCA2 and have not had ...
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical Services, ... solutions for injectable drug administration, today shared the results ... Adapter for improving the intradermal administration of polio vaccines. ... Vaccination Summit in May 2017 by Dr. Ondrej ... Department, World Health Organization (WHO), and recently published in ...
(Date:10/4/2017)... SEOUL, South Korea , Oct. 4, 2017 /PRNewswire/ ... launched its next-generation CPR training aide "cprCUBE" on Kickstarter. ... of chest compression during cardiac arrests with better efficiency ... patient-mannequins. It also offers real-time feedback on efficacy of ... The crowdfunding campaign has a goal to raise ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Dickinson Insurance and ... and financial preparation services, is providing an update on a charitable event that ... City Rescue is a locally recognized nonprofit that provides shelter and care for ...
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important to ... Fortunately, an inventor from Austin, Texas, has identified a solution. , She developed a ... or restricted lighting. As such, it eliminates the need to turn on a light ...
(Date:10/13/2017)... ... 2017 , ... The International Association of Eating Disorders Professionals ... the field of eating disorders, announces the opening of early registration for the ... at the Omni Resort at ChampionsGate. , The annual iaedp™ Symposium ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, ... guideline updates for the primary prevention of cardiovascular diseases during the 15th ...
(Date:10/13/2017)... CT (PRWEB) , ... October 13, 2017 , ... ... long-term care services, staged a mock evacuation of the facility as part of a ... Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as ...
Breaking Medicine News(10 mins):